2. Search Result
Search Result
Results for "

SMI

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16576A
    SMI-4a
    1 Publications Verification

    TCS-PIM-1-4a

    		 Pim Cancer
    SMI-4a (TCS-PIM-1-4a) is a poten, selective, cell-permeable and ATP-competitive Pim-1 inhibitor with an IC50 of 24 μM and a Ki of 0.6 μM. SMI-4a also inhibits Pim-2 (IC50 of 100 μM), and does not significantly inhibit the other serine/threonine- or tyrosine-kinases. SMI-4a has anticancer activity .
    SMI-4a
  • HY-106353
    Smilagenin
    1 Publications Verification

    		 mAChR Endogenous Metabolite Neurological Disease
    Smilagenin (SMI) is a small-molecule steroidal sapogenin from Anemarrhena asphodeloides and Pelargonium hortorum widely used in traditional Chinese medicine for treating chronic neurodegeneration diseases . Smilagenin (SMI) improves memory of aged rats by increasing the muscarinic receptor subtype 1 (M1)-receptor density . Smilagenin (SMI) attenuates Aβ(25-35)-induced neurodegenerationvia stimulating the gene expression of brain-derived neurotrophic factor, may represents a novel therapeutic strategy for AD .
    Smilagenin
  • HY-101947
    SMI-16a
    5 Publications Verification

    PIM1/2 Kinase Inhibitor VI

    		 Pim Cancer
    SMI-16a is a selective Pim kinase inhibitor with IC50 values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.
    SMI-16a
  • HY-148692
    OSM-SMI-10B

    		STAT Cancer
    OSM-SMI-10B a derivative of OSM-SMI-10. OSM-SMI-10B significantly reduces OSM-induced STAT3 phosphorylation in cancer cells upon co-incubation with OSM (Oncostatin M) .
    OSM-SMI-10B
  • HY-112433A
    (S)-NIK SMI1

    		NF-κB Drug Isomer Inflammation/Immunology
    (S)-NIK SMI1 is the isomer of NIK SMI1 (HY-112433), and can be used as an experimental control. NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM.
    (S)-NIK SMI1
  • HY-125025
    SMI 6860766

    		TNF Receptor Metabolic Disease Inflammation/Immunology
    SMI 6860766, a small molecule inhibitor of CD40-TRAF6 interaction, improves glucose tolerance, reduces immune cell accumulation in adipose tissue, and reduces AT inflammation .
    SMI 6860766
  • HY-170817
    SMI-1074

    		Ligands for Target Protein for PROTAC Cancer
    SMI-1074 is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). SMI-1074 can be used for synthesis SMD-3236 (HY-170824) and SMD-1087 (HY-170828) .
    SMI-1074
  • HY-106353R
    Smilagenin (Standard)

    		Reference Standards mAChR Endogenous Metabolite Neurological Disease
    Smilagenin (Standard) is the analytical standard of Smilagenin. This product is intended for research and analytical applications. Smilagenin (SMI) is a small-molecule steroidal sapogenin from Anemarrhena asphodeloides and Pelargonium hortorum widely used in traditional Chinese medicine for treating chronic neurodegeneration diseases . Smilagenin (SMI) improves memory of aged rats by increasing the muscarinic receptor subtype 1 (M1)-receptor density . Smilagenin (SMI) attenuates Aβ(25-35)-induced neurodegenerationvia stimulating the gene expression of brain-derived neurotrophic factor, may represents a novel therapeutic strategy for AD .
    Smilagenin (Standard)
  • HY-116923
    p18SMI-21

    		Endogenous Metabolite Metabolic Disease
    p18SMI-21 is a novel INK4C inhibitor that specifically blocks the biological activity of p18 protein. p18SMI-21 exerts its anti-gastric acid effect through direct contact, and the intensity of this effect varies with the dose. p18SMI-21 can significantly reduce the proteolytic activity of pepsin under certain conditions. The inhibitory effect of p18SMI-21 is best achieved in direct contact with the substrate. If it contacts the substrate first, the inhibitory effect will be lost .
    p18SMI-21
  • HY-148693
    OSM-SMI-8

    NSC642624

    		 Interleukin Related Cancer
    OSM-SMI-8 (NSC642624) is a potent OSM (oncostatin M) antagonist. OSM-SMI-8 has the potential for the research of cancer .
    OSM-SMI-8
  • HY-148692A
    (E/Z)-OSM-SMI-10B

    		STAT Cancer
    (E/Z)-OSM-SMI-10B a derivative of OSM-SMI-10. (E/Z)-OSM-SMI-10B significantly reduces OSM-induced STAT3 phosphorylation in cancer cells upon co-incubation with OSM (Oncostatin M) .
    (E/Z)-OSM-SMI-10B
  • HY-148693A
    (E/Z)-OSM-SMI-8

    (E/Z)-NSC642624

    		 Interleukin Related Cancer
    (E/Z)-OSM-SMI-8 is the racemate of OSM-SMI-8 (HY-148693). OSM-SMI-8 is the antagonist for OSM (oncostatin M), that exhibits the potential in anti-cancer research .
    (E/Z)-OSM-SMI-8
  • HY-112433
    NIK SMI1
    Maximum Cited Publications
    7 Publications Verification

    		 NF-κB Inflammation/Immunology
    NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM. NIK SMI1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NIK SMI1
  • HY-170828
    SMD-1087

    		PROTACs SWI/SNF Complex Others
    SMD-1087 is a PROTAC that selectively targets SMARCA2 (DC50=8 nM, Dmax=89%) and SMARCA4 with a DC50 of 1 μM. SMD-1087 consists of the E3 ligase ligand (S,R,S)-AHPC-Me (blue part) (HY-112078), the target protein ligand SMI-1074 (red part) (HY-170817), and the PROTAC linker (1r,4r)-tert-Butyl 4-(bromomethyl)cyclohexanecarboxylate (black part) (HY-W890392). Among them, its target protein ligand + Linker part corresponds to SMARCA2 Ligand-Linker Conjugate-1 (HY-170829) .
    SMD-1087
  • HY-170824
    SMD-3236

    		PROTACs Epigenetic Reader Domain Cancer
    SMD-3236 is a SMARCA2-targeted PRAOTAC degrader designed based on SMARCA ligands and VHL-1 ligands, with long-lasting antitumor activity in vivo. SMARCA2 is a synthetic lethal target in SMARCA4-deficient cancer cells, and SMD-3236 has a 2000-fold selectivity for degradation of SMARCA2 over SMARCA4, with a DC50< 1 nM and a Dmax>95%. SMD-3236 can induce SMARCA2 loss in tumor tissues while retaining SMARCA4 protein, and inhibit tumor growth in the H838 smarca4-deficient human cancer xenograft model. SMD-3236 is composed of target protein ligand (red part) SMI-1074 (HY-170817), PROTAC linker (black part) (trans-4-Ethynylcyclohexyl)methyl methanesulfonate (HY-170825), and E3 ligase ligand (blue part) SMARCA2 ligand-14 (HY-170826), of which the E3 ligase ligand and linker form a conjugate E3 Ligase Ligand-linker Conjugate 159 (HY-170827) .
    SMD-3236

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: